Intrexon | XON - Current Liabilities


Intrexon reported $23.02M in Current Liabilities for its fiscal quarter ending in June of 2024.





Current Liabilities Change Date
Agenus USD 231.82M 17.42M Jun/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Amgen USD 25.5B 547M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Incyte USD 1.44B 125.72M Sep/2026
Intrexon USD 23.02M 38K Jun/2024
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 46.74M 6.07M Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
MannKind USD 142.9M 8.34M Jun/2026
Merck USD 27.73B 786M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Veracyte USD 62.74M 6.62M Jun/2026
Xencor USD 81.86M 8.41M Jun/2026